UroGen Pharma Ltd. (URGN) Ownership
URGN ownership summary
as of October 18, 2026- Institutions
- 98.0% of shares outstanding
- Insiders
- 3.49% of shares outstanding
- Shares outstanding
- 48.9M
- Float
- 43.4M shares available to trade
- Short interest
- 16.21% 7.8M shares short
- Days to cover
- 10.41 short interest up 24.3% vs prior month
- Institutions 97.98%
- Insiders 3.49%
URGN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LLC | 9.30% | 4.5M | $157.0M | — | June 30, 2026 |
| 2 | BlackRock Inc | 6.55% | 3.2M | $110.6M | +355,894 (+12.5%) | June 30, 2026 |
| 3 | Morgan Stanley - Brokerage Accounts | 5.27% | 2.6M | $89.0M | +16,325 (+0.6%) | June 30, 2026 |
| 4 | Kynam Capital Management, LP | 4.98% | 2.4M | $84.1M | +186,814 (+8.3%) | June 30, 2026 |
| 5 | Jefferies Financial Group Inc | 4.50% | 2.2M | $76.0M | — | June 30, 2026 |
| 6 | SG Americas Securities, LLC | 4.20% | 2.1M | $70.9M | +395,060 (+23.8%) | June 30, 2026 |
| 7 | American Century Companies Inc | 3.45% | 1.7M | $58.3M | +48,149 (+2.9%) | June 30, 2026 |
| 8 | Point72 Asset Management, L.P. | 3.12% | 1.5M | $52.7M | +1.5M (0.0%) | June 30, 2026 |
| 9 | Frontier Capital Management CO Inc | 3.09% | 1.5M | $52.1M | +194,435 (+14.8%) | June 30, 2026 |
| 10 | Opaleye Management Inc | 2.95% | 1.4M | $49.8M | +9,996 (+0.7%) | June 30, 2026 |
| 11 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.66% | 1.3M | $45.0M | −201,066 (−13.4%) | June 30, 2026 |
| 12 | MENORA MIVTACHIM HOLDINGS LIMITED | 2.36% | 1.2M | $39.8M | — | June 30, 2026 |
| 13 | D. E. Shaw & Co LP | 2.34% | 1.1M | $39.6M | +122,660 (+12.0%) | June 30, 2026 |
| 14 | State Street Corp | 2.05% | 1.0M | $34.7M | +128,895 (+14.7%) | June 30, 2026 |
| 15 | MPM Oncology Impact Management LP | 1.91% | 933K | $32.3M | −10,388 (−1.1%) | June 30, 2026 |
| 16 | Soleus Capital Management, L.P. | 1.70% | 830K | $28.7M | +102,810 (+14.1%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 1.68% | 820K | $28.3M | +221,306 (+37.0%) | June 30, 2026 |
| 18 | Migdal Insurance & Financial Holdings Ltd | 1.58% | 771K | $26.6M | — | June 30, 2026 |
| 19 | Orbimed Advisors LLC | 1.38% | 676K | $23.4M | −199,300 (−22.8%) | June 30, 2026 |
| 20 | Geode Capital Management, LLC | 1.25% | 610K | $21.1M | +86,533 (+16.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 3.4M shares and 3 cut 411K.
URGN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RTW Biotech Opportunities Ord | 3.80% | 1.9M | $64.2M | +499,858 (+36.8%) | December 31, 2025 |
| 2 | iShares Russell 2000 ETF | 2.26% | 1.1M | $38.1M | −12,736 (−1.1%) | September 30, 2026 |
| 3 | American Century Small Cap Growth Inv | 1.79% | 875K | $30.2M | — | September 30, 2026 |
| 4 | Fidelity Small Cap Index | 0.95% | 465K | $16.1M | +4,152 (+0.9%) | July 31, 2026 |
| 5 | iShares Russell 2000 Growth ETF | 0.70% | 344K | $11.9M | −435 (−0.1%) | September 30, 2026 |
| 6 | Xtrackers S&P 500 Swap ETF 1C | 0.69% | 335K | $11.6M | +200,817 (+149.3%) | December 31, 2025 |
| 7 | iShares Biotechnology ETF | 0.66% | 324K | $11.2M | −2,456 (−0.8%) | September 30, 2026 |
| 8 | Vanguard Russell 2000 ETF | 0.51% | 248K | $8.6M | +2,883 (+1.2%) | September 30, 2026 |
| 9 | Biotech Growth Ord | 0.46% | 227K | $7.8M | −157,900 (−41.0%) | June 30, 2026 |
| 10 | Vanguard Explorer Value Inv | 0.46% | 225K | $7.8M | +88,466 (+64.9%) | June 30, 2026 |
| 11 | Belfius Equities Cure C Cap | 0.44% | 215K | $7.4M | +11,750 (+5.8%) | March 31, 2026 |
| 12 | Fidelity Enhanced Small Cap Core ETF | 0.43% | 209K | $7.2M | +438 (+0.2%) | September 30, 2026 |
| 13 | State Street® SPDR® Ptf Dev Wld exUS ETF | 0.38% | 188K | $6.5M | — | September 30, 2026 |
| 14 | iShares Micro-Cap ETF | 0.27% | 134K | $4.6M | −927 (−0.7%) | September 30, 2026 |
| 15 | Calamos Timpani Small Cap Growth I | 0.27% | 131K | $4.5M | +33,480 (+34.2%) | August 31, 2026 |
| 16 | Vanguard Health Care ETF | 0.24% | 120K | $4.1M | +1,282 (+1.1%) | September 30, 2026 |
| 17 | Schwab Small Cap Index | 0.21% | 104K | $3.6M | +854 (+0.8%) | August 31, 2026 |
| 18 | Nuveen Quant Small Cap Equity R6 | 0.20% | 98K | $3.4M | +98,500 (0.0%) | August 31, 2026 |
| 19 | Bridge Builder Small/Mid Cap Value | 0.20% | 98K | $3.4M | +94,525 (+2,735.9%) | September 30, 2026 |
| 20 | VALIC Company I Small Cap Growth | 0.20% | 96K | $3.3M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
URGN insider transactions
latest 10| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | Jason Drew Smith | Sell | $19.69 | 7,479 | $147,262 |
| 2026-02-03 | Mark Schoenberg | Sell | $19.69 | 7,373 | $145,174 |
| 2025-11-19 | Mark Schoenberg | Sell | $25.00 | 10,000 | $250,000 |
| 2025-10-08 | Chris Degnan | Sell | $16.85 | 2,203 | $37,121 |
| 2025-09-08 | Jason Drew Smith | Sell | $19.11 | 1,520 | $29,047 |
| 2025-09-08 | Mark Schoenberg | Sell | $19.11 | 871 | $16,645 |
| 2025-08-11 | Mark Schoenberg | Sell | $17.69 | 10,000 | $176,900 |
| 2025-07-28 | Jason Drew Smith | Sell | $19.14 | 7,522 | $143,971 |
| 2025-07-28 | Mark Schoenberg | Sell | $19.14 | 5,149 | $98,552 |
| 2025-06-09 | Mark Schoenberg | Sell | $7.37 | 5,162 | $38,044 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
URGN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns URGN
Institutional investors own 98.0% of UroGen Pharma's shares and insiders 3.49%. The largest holder is RTW INVESTMENTS, LLC with 9.30% of the shares (4.5M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 3 reduced their stake in the latest filings. Short interest is 16.21% of the float, or 10.41 days of average trading volume. The share count rose 2,039.5% since 2014.
Related: URGN analyst forecast, URGN key metrics. See the URGN stock overview for the latest quote and news.
URGN ownership FAQ
Who owns the most UroGen Pharma stock?
The largest shareholders of UroGen Pharma are RTW INVESTMENTS, LLC (9.30%), BlackRock Inc (6.55%), Morgan Stanley - Brokerage Accounts (5.27%), Kynam Capital Management, LP (4.98%), Jefferies Financial Group Inc (4.50%).
What percentage of UroGen Pharma is owned by institutions?
Institutions hold 98.0% of UroGen Pharma's shares outstanding; insiders hold 3.49%.
Which funds own UroGen Pharma?
The largest fund holders of UroGen Pharma are RTW Biotech Opportunities Ord (3.80%), iShares Russell 2000 ETF (2.26%), American Century Small Cap Growth Inv (1.79%), Fidelity Small Cap Index (0.95%), iShares Russell 2000 Growth ETF (0.70%).
What is UroGen Pharma's short interest?
7.8M shares of UroGen Pharma were sold short, 16.21% of the float; at the average daily volume it would take 10.41 days to cover.
Are insiders buying or selling UroGen Pharma?
Of the latest 10 reported insider transactions in UroGen Pharma (since June 9, 2025), 0 were purchases and 10 were sales.
How many shares of UroGen Pharma are outstanding?
UroGen Pharma has 48.9M shares outstanding, of which 43.4M are in the public float.